{"filings":[{"id":78081,"accession_number":"0001193125-26-222899","cik":872912,"company_name":"DELCATH SYSTEMS, INC.","ticker":"DCTH","form_type":"8-K","filed_at":"2026-05-14T12:23:52+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Delcath stockholders approve 1.8M share increase to equity plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected Elizabeth Czerepak and John R. Sylvester as Class II directors for 3-year terms.","Amendment to 2020 Omnibus Equity Incentive Plan approved; 1,800,000 new shares authorized.","Ratification of CBIZ CPAs P.C. as independent auditor for FY2026 approved with 22.7M votes for.","Advisory vote on named executive officer compensation passed with 13.2M for vs 1.7M against.","Approximately 67.4% of eligible shares were represented at the meeting; broker non-votes totaled ~8.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":381992390.9247204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99308,"accession_number":"0001628280-26-031725","cik":872912,"company_name":"DELCATH SYSTEMS, INC.","ticker":"DCTH","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Delcath Q1 2026 revenue $25M (+26% YoY); net loss $1.1M; guides FY rev at least $100M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $25.0M, up 26% YoY; HEPZATO KIT revenue $23.3M (+29% YoY); CHEMOSAT $1.7M (flat).","Net loss of $1.1M vs net income $1.1M prior year; non-GAAP adjusted EBITDA $3.4M vs $7.6M.","Cash and investments $89.3M, no debt; repurchased 316,023 shares for $3.0M in Q1.","FY 2026 guidance: revenue at least $100M, gross margins 84-87%, positive adjusted EBITDA.","Active centers 29; CHOPIN Phase 2 trial published in The Lancet Oncology; ESMO guideline inclusion."],"consensus_eps_estimate":-0.0884,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":24994000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":381992390.9247204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115227,"accession_number":"0001193125-26-088527","cik":872912,"company_name":"DELCATH SYSTEMS, INC.","ticker":"DCTH","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Delcath's CHOPIN trial published: PHP+immunotherapy shows 54.7% vs 15.8% 1-year PFS","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-year PFS 54.7% vs 15.8% (adjusted HR 0.34; p=0.0002); median PFS 12.8 vs 8.3 months.","Median OS 23.1 vs 19.6 months (HR 0.39; p=0.0065); 2-year OS 49.6% vs 22.1%.","Objective response rate 76.3% vs 39.5%; complete response rate 13% vs 3%.","Grade ≥3 treatment-related AEs 82% (combo) vs 41% (PHP alone); one treatment-related death in combo arm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":381992390.9247204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115226,"accession_number":"0001628280-26-012004","cik":872912,"company_name":"DELCATH SYSTEMS, INC.","ticker":"DCTH","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Delcath reports FY2025 revenue $85.2M, net income $2.7M; guides FY2026 revenue ≥$100M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 total revenue $85.2M, up 129% YoY ($37.2M); HEPZATO revenue $78.8M, CHEMOSAT $6.4M.","Full-year net income $2.7M vs net loss $26.4M in 2024; adjusted EBITDA $25.1M.","Cash $91.0M, no debt; repurchased 628,572 shares for $6.0M.","FY2026 guidance: total revenue at least $100M, HEPZATO volume growth ≥20%, gross margin 84-87%.","28 active centers; 140% procedure volume growth in 2025; publications including CHOPIN study."],"consensus_eps_estimate":-0.0629,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":85231000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":381992390.9247204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115225,"accession_number":"0001193125-26-010498","cik":872912,"company_name":"DELCATH SYSTEMS, INC.","ticker":"DCTH","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Delcath prelim FY2025 revenue $85.2M, HEPZATO $78.8M, cash $91M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q4 revenue ~$20.7M, FY revenue ~$85.2M; HEPZATO KIT Q4 ~$19.0M, FY ~$78.8M.","CHEMOSAT Q4 revenue ~$1.7M, FY ~$6.4M.","Cash and short-term investments ~$91.0M as of Dec 31, 2025; no debt.","628,572 shares repurchased for $6.0M under $25M buyback program.","25 active sites; ~140% growth in HEPZATO procedure volume YoY; positive operating cash flow in Q4."],"consensus_eps_estimate":-0.0629,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":85231000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":381992390.9247204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131647,"accession_number":"0001193125-25-289917","cik":872912,"company_name":"DELCATH SYSTEMS, INC.","ticker":"DCTH","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Delcath Systems board authorizes $25 million share repurchase program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized repurchase of up to $25M of common stock on November 19, 2025.","Repurchases may occur from time to time, subject to market conditions.","Program is part of capital allocation strategy and does not obligate any repurchases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":381992390.9247204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131646,"accession_number":"0001628280-25-048539","cik":872912,"company_name":"DELCATH SYSTEMS, INC.","ticker":"DCTH","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Delcath Q3 2025 revenue $20.6M (+84% YoY); net income $0.8M; FY revenue guidance $83-85M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total revenue $20.6M (+84% YoY); HEPZATO revenue $19.3M, CHEMOSAT $1.3M.","Net income $0.8M (down from $1.9M YoY) due to higher R&D ($8M vs $3.9M) and SG&A ($10.3M vs $7M).","Non-GAAP adjusted EBITDA $5.3M (vs $1M YoY); cash & investments $88.9M, no debt.","FY 2025 guidance: revenue $83-85M (150% volume growth), gross margins 85-87%, positive EBITDA & cash flow each quarter.","Clinical progress: Phase 2 CRC trial dosed first patient; CHOPIN trial showed improved survival; 25 active U.S. centers."],"consensus_eps_estimate":0.0204,"consensus_eps_actual":0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":64503000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":381992390.9247204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131645,"accession_number":"0001193125-25-242909","cik":872912,"company_name":"DELCATH SYSTEMS, INC.","ticker":"DCTH","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Delcath: Q3 prelim rev $20.5M, net income $0.8M; CHOPIN trial meets endpoint","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Prelim Q3 rev $20.5M ($19.2M HEPZATO, $1.3M CHEMOSAT); net income $0.8M; adj EBITDA $5.3M; cash $88.9M, no debt.","FY2025 rev guidance raised to $83-85M, reflecting ~150% treatment volume increase over 2024.","CHOPIN trial met primary endpoint: 1-yr PFS 54.7% (combo) vs 15.8% (PHP alone); HR 0.34, p<0.001.","Secondary endpoints: 2-yr OS 49.6% vs 22.1% (HR 0.39, p=0.006); ORR 76.3% vs 39.5% (p<0.001).","Grade 3+ AEs higher in combo (81.6% vs 40.5%) but manageable; no new safety signals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":381992390.9247204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148212,"accession_number":"0001193125-25-181881","cik":872912,"company_name":"DELCATH SYSTEMS, INC.","ticker":"DCTH","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Delcath Systems amends bylaws to clarify stockholder nomination procedures and indemnification rights","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board amended and restated Bylaws on August 12, 2025, effective immediately.","Clarified procedural and informational requirements for stockholder nominations and proposals.","Updated provisions on election of officers and Chairperson duties.","Described indemnification rights for directors, officers, and agents.","Incorporated administrative changes including notice periods and remote communications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":381992390.9247204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148211,"accession_number":"0001628280-25-038098","cik":872912,"company_name":"DELCATH SYSTEMS, INC.","ticker":"DCTH","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Delcath Q2 revenue jumps 210% to $24.2M; net income $2.7M vs loss; FY25 guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $24.2M (+210% YoY); HEPZATO KIT revenue $22.5M, CHEMOSAT $1.7M.","Net income $2.7M vs net loss $13.7M; Non-GAAP adj. EBITDA $9.8M vs loss $0.8M.","FY2025 revenue guidance raised to $93-96M; gross margins 83-85%; positive EBITDA and cashflow each quarter.","Cash and investments $81.0M, no debt; activated 3 new U.S. centers (20 total, 10 accepting referrals).","Received EU/UK authorization for clinical study of HEPZATO in metastatic colorectal cancer."],"consensus_eps_estimate":0.0255,"consensus_eps_actual":0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":43940000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":381992390.9247204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166983,"accession_number":"0001193125-25-124538","cik":872912,"company_name":"DELCATH SYSTEMS, INC.","ticker":"DCTH","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Delcath issues 2025 revenue guidance of $94-98M, plans to enter Medicaid drug rebate agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Revenue guidance $94-98M, >150% YoY growth.","Gross margin 83-85%; positive adjusted EBITDA and cash flow each quarter in 2025.","Plans to enter NDRA with CMS, effective Q3 2025, expanding Medicaid/340B access.","CEO expects HEPZATO treatment volume to increase at least 200% in 2025 vs 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":381992390.9247204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166982,"accession_number":"0001193125-25-121700","cik":872912,"company_name":"DELCATH SYSTEMS, INC.","ticker":"DCTH","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Delcath Systems shareholders approve equity plan amendments and director elections at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders elected Gerard Michel and Gilad Aharon as Class I directors.","Approved amendment to 2020 Omnibus Equity Incentive Plan, adding 2.2M shares.","Approved amendment to 2021 Employee Stock Purchase Plan, adding 300K shares.","Ratified CBIZ CPAs P.C. as independent auditor for fiscal year 2025.","Approved non-binding advisory vote on named executive officer compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":381992390.9247204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166981,"accession_number":"0001628280-25-023470","cik":872912,"company_name":"DELCATH SYSTEMS, INC.","ticker":"DCTH","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Delcath Q1 revenue surges to $19.8M, posts net income of $1.1M vs loss a year ago","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $19.8M (vs $3.1M Q1 2024); HEPZATO KIT sales $18.0M, CHEMOSAT $1.8M.","Net income $1.1M vs net loss of $11.1M in prior-year quarter; gross margin 86%.","Non-GAAP adjusted EBITDA $7.6M vs loss of $7.3M in Q1 2024.","Cash and investments $58.9M, no debt; exercise of Series F warrants added $16.2M.","19 active U.S. centers; FDA cleared IND for phase 2 HEPZATO in metastatic breast cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":19784000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":381992390.9247204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184366,"accession_number":"0001193125-25-060237","cik":872912,"company_name":"DELCATH SYSTEMS, INC.","ticker":"DCTH","form_type":"8-K","filed_at":"2025-03-21T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Delcath Systems replaces auditor Marcum with CBIZ CPAs effective March 18, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum LLP resigned on March 18, 2025; CBIZ CPAs P.C. engaged as new independent auditor immediately.","No disagreements or reportable events with Marcum for fiscal years 2023, 2024, and through resignation.","The 2023 audit report included a going-concern explanatory paragraph about substantial doubt.","Audit Committee approved the engagement for the fiscal year ending December 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":381992390.9247204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184365,"accession_number":"0001628280-25-010775","cik":872912,"company_name":"DELCATH SYSTEMS, INC.","ticker":"DCTH","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Delcath Q4 revenue $15.1M, positive adjusted EBITDA; FY revenue $37.2M, no debt","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $15.1M ($13.7M HEPZATO US, $1.4M CHEMOSAT Europe); FY total $37.2M.","Q4 net loss narrowed to $3.4M from $11.1M; FY net loss $26.4M from $47.7M.","Q4 non-GAAP adjusted EBITDA positive $4.6M; FY adjusted EBITDA loss $2.5M.","Year-end cash & investments $53.2M; no debt; warrant exercises generated $41.3M in 2024.","16 active US centers; FDA clearance for Phase 2 HEPZATO trial in mCRC; NCCN update recommends HEPZATO for mUM."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":381992390.9247204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184364,"accession_number":"0001193125-25-005053","cik":872912,"company_name":"DELCATH SYSTEMS, INC.","ticker":"DCTH","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Delcath announces preliminary Q4/FY2024 revenue of $15.1M/$37.2M; cash $53.2M, no debt","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue ~$15.1M; FY2024 total revenue ~$37.2M.","HEPZATO KIT Q4 rev $13.7M, FY $32.3M; CHEMOSAT Q4 $1.4M, FY $4.9M.","Gross margins expected 80%-85%.","Cash, cash equivalents & ST investments $53.2M; no debt as of Dec 31, 2024.","14 active HEPZATO KIT sites; 36.2M shares outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":37205000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":381992390.9247204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200958,"accession_number":"0001193125-24-286248","cik":872912,"company_name":"DELCATH SYSTEMS, INC.","ticker":"DCTH","form_type":"8-K","filed_at":"2024-12-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Delcath Systems receives $16.3M from Series E and E1 warrant exercises","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1,746,424 warrants exercised; 1,045,157 shares of common stock and 603,954 pre-funded warrants issued.","Gross proceeds of approximately $16.3 million; ~6.6% of exercises were cashless.","Warrants had $10.00 exercise price, issued in July/August 2019, expired Dec 24, 2024.","CEO states cash position strong to fund HEPZATO commercialization and clinical trials.","Warrant amendments allow pre-funded warrants to avoid exceeding 9.99% beneficial ownership cap."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":381992390.9247204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200957,"accession_number":"0001628280-24-046513","cik":872912,"company_name":"DELCATH SYSTEMS, INC.","ticker":"DCTH","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Delcath Q3 revenue $11.2M (+44% QoQ); HEPZATO adoption grows; debt-free after warrant exercise","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total revenue $11.2M (vs $0.4M prior year); HEPZATO $10.0M, CHEMOSAT $1.2M.","Activated 12 HEPZATO treatment centers in U.S.; additional centers in training pipeline.","Ended Q3 with $14.0M cash; quarterly cash burn $3.6M.","Post-Q3: paid $2.8M final Rosalind note; ~$25M from Tranche B warrant exercise; no debt.","Advancing HEPZATO programs for liver-dominant colorectal and breast cancers."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":22105000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":381992390.9247204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200956,"accession_number":"0001193125-24-238564","cik":872912,"company_name":"DELCATH SYSTEMS, INC.","ticker":"DCTH","form_type":"8-K","filed_at":"2024-10-17T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Delcath reports preliminary Q3 revenue $11.2M; HEPZATO KIT sales trigger $25M warrant exercise","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q3 2024 revenue of $11.2M, including $10M U.S. sales from HEPZATO KIT.","Announcement of $10M U.S. quarterly revenue triggers exercise of Tranche B warrants from March 2023 PIPE.","Warrant holders have 21 days to exercise at $6/share for aggregate $25M.","Proceeds to support HEPZATO KIT commercial launch and fund new clinical trials for expanded indications.","Final Q3 results and business update scheduled for investor call on November 8, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":22105000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":381992390.9247204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216973,"accession_number":"0001193125-24-209296","cik":872912,"company_name":"DELCATH SYSTEMS, INC.","ticker":"DCTH","form_type":"8-K","filed_at":"2024-08-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Delcath Systems Announces Positive Independent Study Results for Liver-Directed Therapy in Uveal Melanoma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Study of 167 patients showed median melanoma-specific survival of 28 months with first-line liver-directed therapy vs 10 months with systemic therapy.","Patients diagnosed 2016-2021 receiving liver-directed therapy had median MSS of 30 months, compared to 20 months for 2005-2015 cohort.","CHEMOSAT Hepatic Delivery System was used in the study; 30 of 56 patients in 2016-2021 period received CHEMOSAT.","Study published in Therapeutic Advances in Medical Oncology, conducted by University of Tübingen researchers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":381992390.9247204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216972,"accession_number":"0001193125-24-208282","cik":872912,"company_name":"DELCATH SYSTEMS, INC.","ticker":"DCTH","form_type":"8-K","filed_at":"2024-08-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Delcath reports positive results from two independent studies on CHEMOSAT and HEPZATO KIT in liver cancers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CHEMOSAT study: 91% disease control rate, 18.2% complete response in liver tumors; median hepatic PFS 52 weeks overall.","CHEMOSAT in uveal melanoma: median hepatic PFS 69 weeks; in cholangiocarcinoma: 38 weeks.","HEPZATO KIT first-line: median OS 22.4 months, hepatic PFS 17.6 months vs 8.8 months for immunotherapy.","HEPZATO KIT second-line: median PFS 22.2 months; hepatic PFS not reached vs 14.7 months for immunotherapy.","Both studies published in peer-reviewed journals (ESMO GI and Annals of Surgical Oncology)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":381992390.9247204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216971,"accession_number":"0001628280-24-034736","cik":872912,"company_name":"DELCATH SYSTEMS, INC.","ticker":"DCTH","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Delcath Q2 revenue $7.8M vs $0.5M YoY; HEPZATO KIT generates $6.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $7.8M ($6.6M HEPZATO US, $1.2M CHEMOSAT Europe) vs $0.5M prior year.","Cash and investments $19.9M; final principal payment submitted to Avenue Venture.","Activated 8 US treating centers; received CMS NTAP status for HEPZATO (Aug 1, 2024).","Appointed Dr. Bridget Martell to Board; extended melphalan supply agreement to 2028.","FOCUS study results published in Annals of Surgical Oncology; accepted for ESMO poster."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":10905000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":381992390.9247204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216970,"accession_number":"0001193125-24-181630","cik":872912,"company_name":"DELCATH SYSTEMS, INC.","ticker":"DCTH","form_type":"8-K","filed_at":"2024-07-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Delcath Systems enters new employment agreements with CEO Michel, SVP Pennell, and GM Muir","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Michel's new agreement provides for 15 months severance (18 months if change in control) and performance bonus eligibility.","SVP Finance Pennell's agreement provides for 12 months severance (12 months if change in control) and bonus eligibility.","GM Oncology Muir's agreement provides for 12 months severance (12 months if change in control) and bonus eligibility.","These agreements replace prior agreements and include standard non-disclosure, non-solicitation, and non-disparagement provisions.","No changes in roles or base salary amounts disclosed; executives continue in current positions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":381992390.9247204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216969,"accession_number":"0001193125-24-176589","cik":872912,"company_name":"DELCATH SYSTEMS, INC.","ticker":"DCTH","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Delcath regains Nasdaq compliance with audit committee composition rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Delcath on July 8, 2024 that it regained compliance with Listing Rule 5605.","Company had been out of compliance since May 29, 2024 due to insufficient independent directors on Audit Committee.","Compliance restored by appointing Dr. Bridget Martell to the Audit Committee on July 2, 2024.","Deadline to cure was May 23, 2025; early resolution avoids potential delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":381992390.9247204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236715,"accession_number":"0001193125-24-149142","cik":872912,"company_name":"DELCATH SYSTEMS, INC.","ticker":"DCTH","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["3.01","5.07","5.02","9.01"],"status":"ready","headline":"Delcath Systems appoints Bridget Martell to board; faces Nasdaq audit committee non-compliance","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Roger Stoll retired from board on May 23; Audit Committee now has only two members, violating Nasdaq Rule 5605(c)(2).","Cure period to regain compliance runs until earlier of next annual meeting or May 23, 2025.","Bridget Martell, MA, MD appointed as Class III director, effective May 23, 2024; press release issued May 28.","Stockholders approved amendment to 2020 Omnibus Equity Incentive Plan, increasing shares available by 2,000,000.","Steven Salamon elected as Class III director; Marcum LLP ratified as auditor; advisory vote on compensation passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":381992390.9247204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236714,"accession_number":"0001628280-24-023065","cik":872912,"company_name":"DELCATH SYSTEMS, INC.","ticker":"DCTH","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Delcath Systems Q1 2024 revenue jumps to $3.1M; raises center activation target to 20 by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.1M, up from $0.6M YoY, driven by HEPZATO KIT sales of $2.0M and CHEMOSAT of $1.1M.","Raised $7.0M in private placement; cash and investments total $27.2M at quarter end.","Appointed Dr. Martha S. Rook as COO; expanded center activation goal to 20 by end of 2024.","Received permanent J-code (J9248) and pass-through payment for HEPZATO KIT from CMS effective April 1.","SG&A rose to $8.8M from $4.2M due to commercial launch; R&D decreased to $3.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":3139000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":381992390.9247204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236713,"accession_number":"0001193125-24-115922","cik":872912,"company_name":"DELCATH SYSTEMS, INC.","ticker":"DCTH","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Delcath Systems extends melphalan supply agreement through Dec 2028; modifies pricing terms","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Term extended to December 31, 2028; effective May 1, 2024.","Purchase orders for melphalan HCl must be placed at least 210 days before delivery.","Price per vial modified; annual increases tied to pharmaceutical preparation PPI.","Agreement with Synerx Pharma, LLC and Mylan Teoranta for key drug supply.","Fifth Amendment dated April 22, 2024, ensures long-term supply continuity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":381992390.9247204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254351,"accession_number":"0001628280-24-012996","cik":872912,"company_name":"DELCATH SYSTEMS, INC.","ticker":"DCTH","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Delcath Systems reports Q4/FY2023 results; first HEPZATO KIT use, site guidance raised to 20","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["First commercial HEPZATO KIT treatment for metastatic uveal melanoma performed at Moffitt Cancer Center.","Increased 2024 active treatment site guidance from 15 to 20 sites; three sites activated, four more imminent.","Product-specific J-code (J9248) and transitional pass-through payment effective April 1, 2024, from CMS.","Appointed Dr. Martha S. Rook as COO; raised $7.0M in private placement from insiders and existing investors.","Cash $32.5M at Dec 31, 2023; FY2023 revenue $2.1M (down from $2.7M); SG&A increased to $22.1M for commercial prep."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":381992390.9247204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254350,"accession_number":"0001193125-24-071355","cik":872912,"company_name":"DELCATH SYSTEMS, INC.","ticker":"DCTH","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Delcath Systems raises $7M via private placement of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 876,627 shares at $3.72/share and 1,008,102 pre-funded warrants at $3.71 each.","Gross proceeds of approximately $7 million; net proceeds for working capital and general corporate purposes.","Closing on March 19, 2024; participants include existing investors, executives, and board members.","Registration rights agreement to file resale registration statement by May 13, 2024.","Securities issued in reliance on Regulation D exemption; unregistered at issuance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":381992390.9247204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254349,"accession_number":"0001193125-24-070787","cik":872912,"company_name":"DELCATH SYSTEMS, INC.","ticker":"DCTH","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Delcath appoints Martha Rook as COO effective March 18, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Martha Rook appointed COO; succeeds John Purpura who is retiring after consulting transition.","Rook brings 25+ years experience from insitro, Sigilon, MilliporeSigma; Ph.D. in biochemistry from MIT.","Compensation: $425,000 base salary, up to 40% bonus, 125,000 options vesting over 36 months.","Purpura enters 6-month consulting agreement; 91,596 options vest over period, expiry extended to Sep 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":381992390.9247204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}